CTLA4 and neoplasm: On the other hand, tremelimumab is a new CTLA-4-targeted IgG2 monoclonal antibody with less antibody-dependent cell-mediated cytotoxicity (ADCC) and also showed anti-tumor effect in clinical trials and is supported by a murine surrogate antibodies experiment, which showed that anti-tumor effect was not completely dependent on ADCC (119).